Obviously they have changed tack to get into the Orphan Drug Application Scene which can fast track.
Still awaiting developments now 2018 has passed unless it has been filed already and we are waiting for approval.
From the AGM Presentation
Complete pre-clinical development and file for orphan drug application in 2018 •
Pre-clinical evidence in FSGS has been developed with CAB102 •
Focus is to file orphan application and secure further value in the asset portfolio •
Seek partnerships to enter clinical development once orphan designation is received
CDY Price at posting:
26.0¢ Sentiment: Buy Disclosure: Held
